HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orr-Urtreger, A. Articles by Giladi, N. Search for Related Content PubMed PubMed Citation Articles by Orr-Urtreger, A. Articles by Giladi, N. Related Collections All Clinical Neurology Parkinson's disease/Parkinsonism All epidemiology Risk factors in epidemiology All Genetics Association studies in genetics

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease

Is there a gender effect?

From The Genetic Institute (A.O.-U., C.S., U.R., S.R., D.B., H.Y.-M., A.B.-S.) and Movement Disorders Unit, Parkinson Center, Department of Neurology (C.S., T.G., N.G.), Tel-Aviv Sourasky Medical Center; and The Sackler Faculty of Medicine (A.O.-U., C.S., T.G., N.G.), Tel-Aviv University, Tel-Aviv, Israel.

Address correspondence and reprint requests to Dr. Avi Orr-Urtreger, Director, Genetic Institute, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel aviorr{at}tasmc.health.gov.il

Background: Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic determinant of Parkinson disease (PD) identified to date, and have been implicated in both familial and sporadic forms of the disease. The G2019S change in LRRK2 exon 41 has been associated with disease at varying frequencies in Asian, European, North American, and North African populations, and is particularly prevalent among Ashkenazi Jews.

Methods: We assessed the occurrence of the LRRK2 G2019S, I2012T, I2020T, and R1441G/C/H mutations in our cohort of Jewish Israeli patients with PD, and determined the LRRK2 haplotypes in 76 G2019S-carriers detected and in 50 noncarrier Ashkenazi patients, using six microsatellite markers that span the entire gene.

Results: Only the G2019S mutation was identified among our patients with PD, 14.8% in the Ashkenazi and 2.7% in the non-Ashkenazi patients, and in 26% and 10.6% of the Ashkenazi familial and apparently sporadic cases. The carrier frequencies in the Ashkenazi and non-Ashkenazi control samples were 2.4% and 0.4%. A common shared haplotype was detected in all non-Ashkenazi and half-Ashkenazi carriers and in all full-Ashkenazi carriers tested, except two. Women and patients with a positive family history of PD were significantly over-represented among the G2019S mutation carriers. Age at disease onset was similar in carriers and noncarriers.

Conclusions: Our data suggest that the LRRK2 G2019S mutation plays an important role in the causality of familial and sporadic Parkinson disease (PD) in Israel and that gender affects its frequency among patients. Although testing symptomatic patients may help establish the diagnosis of PD, the value of screening asymptomatic individuals remains questionable until the penetrance and age-dependent risk of this mutation are more accurately assessed, and specific disease prevention or modifying interventions become available.

GLOSSARY: LRRK2 = leucine-rich repeat kinase 2; PD = Parkinson disease.

Supported by grants from M.K. Humanitarian Fund, National Parkinson Foundation, Miami, FL, Tel Aviv Sourasky Medical Center Grant of Excellence, and Wolfson Foundation.

Disclosure: The authors report no conflicts of interest.

Received October 24, 2006. Accepted in final form May 4, 2007.

This article has been cited by other articles:

				S. Lesage and A. Brice Parkinson's disease: from monogenic forms to genetic susceptibility factors Hum. Mol. Genet., April 15, 2009; 18(R1): R48 - R59. [Abstract] [Full Text] [PDF]

				Z. Gan-Or, N. Giladi, U. Rozovski, C. Shifrin, S. Rosner, T. Gurevich, A. Bar-Shira, and A. Orr-Urtreger Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset Neurology, June 10, 2008; 70(24): 2277 - 2283. [Abstract] [Full Text] [PDF]